Epigenetic changes in the promoter region have the potential to change the expression of genes 34 and statins were shown to induce epigenetic changes in cancer cells.35 To analyse if statin treatment might have effects on chromatin organisation, we determined the accessibility of the IL‐33 promoter in fluvastatin‐treated HACM. The gene discussed is IL33; the disease is cancer.